| http://www.w3.org/ns/prov#value | - This document contains forward-looking statements that involve risks and uncertainties including with respect to Faber???s development of pSivida???s technologies for infectious diseases and disease of the ear; the major global pharma???s acquiring a license to pSivida???s drug delivery technology; the potential signing of definitive agreements with Nordic on the terms described; the amount of pSi
|
